AMPH vs SRPT · P/E 12, rev $732.0M vs rev $1.90B
Amphastar P (AMPH) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Amphastar P (AMPH) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported AMPH revenue for 2024-12-31 was $732.0M. Net income was $159.5M. Revenue was up 13.6% from 2023-12-31 to 2024-12-31. AMPH currently screens at market cap $880.1M and trailing P/E 12.0.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
AMPH currently screens at market cap $880.1M and trailing P/E 12.0. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the AMPH and SRPT stock pages for the full models.
Not investment advice.